TITLE

Harnessing the RNA interference pathway to advance treatment and prevention of hepatocellular carcinoma

AUTHOR(S)
Arbuthnot, Patrick; Thompson, Liam Jed; Piscaglia, Anna C.
PUB. DATE
March 2008
SOURCE
World Journal of Gastroenterology;3/21/2008, Vol. 14 Issue 11, p1670
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Primary liver cancer is the fifth most common malignancy in the world and is a leading cause of cancer-related mortality. Available treatment for hepatocellular carcinoma (HCC), the commonest primary liver cancer, is rarely curative and there is a need to develop therapy that is more effective. Specific and powerful gene silencing that can be achieved by activating RNA interference (RNAi) has generated enthusiasm for exploiting this pathway for HCC therapy. Many studies have been carried out with the aim of silencing HCC-related cellular oncogenes or the hepatocarcinogenic hepatitis B virus (HBV) and hepatitis C virus (HCV). Proof of principle studies have demonstrated promising results, and an early clinical trial assessing RNAi-based HBV therapy is currently in progress. Although the data augur well, there are several significant hurdles that need to be overcome before the goal of RNAi-based therapy for HCC is realized. Particularly important are the efficient and safe delivery of RNAi effecters to target malignant tissue and the limitation of unintended harmful non-specific effects.
ACCESSION #
31436357

 

Related Articles

  • Bioreducible PEI-siRNA Nanocomplex for Liver Cancer Therapy: Transfection, Biodistribution, and Tumor Growth Inhibition In Vivo. Wei Xia; Yan Li; Bo Lou; Peijun Wang; Xiaolong Gao; Chao Lin // Journal of Nanomaterials;2013, p1 

    A bioreducible polyethylenimine (SS-PEI) was successfully applied as a nonviral carrier for the delivery of plasmid DNA and VEGF-siRNA in vitro and in vivo. The SS-PEI could strongly condense DNA or siRNA into nanosized complexes (below 200 nm) with positive surface charges. In vitro...

  • Pharmacologic reversal of epigenetic silencing of the anticancer protein BRM: a novel targeted treatment strategy. Gramling, S; Rogers, C; Liu, G; Reisman, D // Oncogene;7/21/2011, Vol. 30 Issue 29, p3289 

    Tumor suppressor genes and oncogenes are both commonly altered during carcinogenesis. For oncogenes and other genes that drive growth, targeting mutated or activated forms (such as the EGFR-Her2/Nneu pathway) has been shown to be an effective anti-cancer approach. Pharmacologically targeting...

  • Intronic MicroRNA (miRNA). Shi-Lung Lin; Miller, Joseph D.; Shao-Yao Ying // Journal of Biomedicine & Biotechnology;2006 Special Issue 3, p1 

    Nearly 97% of the human genome is composed of noncoding DNA, which varies from one species to another. Changes in these sequences often manifest themselves in clinical and circumstantial malfunction. Numerous genes in these non-protein-coding regions encode microRNAs, which are responsible for...

  • Long non-coding RNA TUG1 is up-regulated in hepatocellular carcinoma and promotes cell growth and apoptosis by epigenetically silencing of KLF2. Ming-De Huang; Wen-Ming Chen; Fu-Zhen Qi; Ming Sun; Tong-Peng Xu; Pei Ma; Yong-qian Shu // Molecular Cancer;9/4/2015, Vol. 14 Issue 1, p1 

    Background: Hepatocellular carcinoma (HCC) is one of the leading causes of cancer-related death worldwide, and the biology of this cancer remains poorly understood. Recent evidence indicates that long non-coding RNAs (lncRNAs) are found to be dysregulated in a variety of cancers, including HCC....

  • Applications of RNA interference in cancer therapeutics as a powerful tool for suppressing gene expression. Song He; Dechun Zhang; Fang Cheng; Fanghong Gong; Yanan Guo // Molecular Biology Reports;Nov2009, Vol. 36 Issue 8, p2153 

    Abstract  Cancer poses a tremendous therapeutic challenge worldwide, highlighting the critical need for developing novel therapeutics. A promising cancer treatment modality is gene therapy, which is a form of molecular medicine designed to introduce into target cells genetic material with...

  • DNA methylation-associated silencing of tumor-suppressor microRNAs in cancer. Lopez-Serra, P; Esteller, M // Oncogene;3/29/2012, Vol. 31 Issue 13, p1609 

    MicroRNAs (miRNAs) are recognized as being central players in many biological processes and cellular pathways. Their roles in disease have been highlighted first by observation of their aberrant expression profiles in human tumors, and then by in vitro and in vivo functional studies in...

  • LIM-class homeobox gene Lim1, a novel oncogene in human renal cell carcinoma. Dormoy, V; Béraud, C; Lindner, V; Thomas, L; Coquard, C; Barthelmebs, M; Jacqmin, D; Lang, H; Massfelder, T // Oncogene;4/14/2011, Vol. 30 Issue 15, p1753 

    Human clear cell renal cell carcinoma (CCC) remains resistant to therapies. The transcription factor LIM-class homeobox gene Lim1 is required for normal organogenesis, including nephrogenesis, by regulating cell movements, differentiation and growth. Its expression is controlled partly by the...

  • siRNA therapeutics: big potential from small RNAs. Ryther, RCC; Flynt, A S; Phillips, J A; Patton, J G // Gene Therapy;Jan2005, Vol. 12 Issue 1, p5 

    RNA interference (RNAi) is now an umbrella term referring to post-transcriptional gene silencing mediated by either degradation or translation arrest of target RNA. This process is initiated by double-stranded RNA with sequence homology driving specificity. The discovery that 21-23 nucleotide...

  • Modulation of miRNA activity in human cancer: a new paradigm for cancer gene therapy? Tong, A. W.; Nemunaitis, J. // Cancer Gene Therapy;Jun2008, Vol. 15 Issue 6, p341 

    MicroRNAs (miRNAs) were discovered more than a decade ago as noncoding, single-stranded small RNAs (∼22 nucleotides) that control the timed gene expression pattern in Caenorhabditis elegans life cycle. A number of these evolutionarily conserved, endogenous miRNAs have been shown to regulate...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics